Glaukos COO shares product updates, 2021 pipeline

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

Related Content:

Therapeutic GlaucomaGlaucomaTechnology

Patient Case #1: 58-year-old patient with open angle glaucoma utilizing minimally invasive glaucoma surgery procedure

How quality vision builds a foundation for safety and everyday activities

Extended depth-of-field lenses: Understanding a new player in cataract surgery